Skip to main content
TipRanks
Go Ultimate75% OFF

10x Genomics (0A88) AI Stock Analysis

6 Followers
GB:0A88

10x Genomics

(LSE:0A88)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue Growth and Gross MarginsAccelerating revenue and healthy, relatively stable gross margins indicate stronger adoption of the company’s platforms and a favorable underlying business model. If sustained, this combination can support reinvestment in product development while improving the company’s ability to convert growth into future earnings.
Negative Factors
Persistent Net LossesDespite improved revenue and cash generation, continued net losses show that the business has not yet established durable earnings profitability. This limits internal funding capacity over time and leaves results more dependent on maintaining growth and controlling expenses as the platform portfolio expands.

10x Genomics (0A88) vs. iShares MSCI United Kingdom ETF (EWC)

-100%0%100%200%300%400%500%GB:0A88+236.86%EWC+17.53%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$6.84B
Dividend Yield
―
Average Volume (3M)
5,176
Price to Earnings (P/E)
-107.7
Beta (1Y)
1.19
Revenue Growth
-3.62%
EPS Growth
16.67%
Country
UK
Employees
1,178
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

10x Genomics Business Overview & Revenue Model

Company Description

Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated inst...

10x Genomics Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:-5.55%|Next Earnings Date:Feb 17, 2027
Earnings Call SentimentPositive

The call was strongly positive overall. Management reported raised revenue guidance, strong consumables performance, growing Atera demand, broad customer interest, expanding AI-related opportunities, improving cash generation and progress across product and clinical initiatives. The main negatives were modest 1% total revenue growth, substantial instrument revenue declines, near-term gross margin compression from the Atera ramp, Apex-related top-line pressure and production and installation constraints.

Positive Updates

Atera Commercial Launch and Strong Customer Demand
10x Genomics began commercial shipments of Atera in September. Management said customer enthusiasm, order flow and demand momentum have continued to build, with demand not viewed as the bottleneck.

Negative Updates

Modest Overall Revenue Growth
Third-quarter revenue was $150.7 million, representing only 1% year-over-year growth.

Company Guidance

Management raised its 2026 revenue outlook to the range of $625 million to $635 million, up from $610 million to $630 million, representing 4% to 6% growth over the full year 2025 excluding nonrecurring revenue related to patent litigation settlements in both 2026 and 2025; it now expects to ship approximately 50 Atera instruments by year-end, up from the previous expectation of approximately 40, and said 50 a quarter between those constraints is about the right number going into next year. Gross margins are expected to be in the low to mid-60s for Q4, while 2027 margins will most likely come in lower than where they are because it will be an instrument heavy year and consumables will start to ramp during the course of the year; Spatial consumables in Q4 are expected to still be double digits for sure, with a full quarter of Atera consumables shipments.

10x Genomics Risk Analysis

10x Genomics disclosed 10 risk factors in its most recent earnings report. 10x Genomics reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks
1.Securities analysts may not publish favorable research or reports about our business or may publish no information at all, which could cause our stock price or trading volume to decline.Q3, 2026
2.We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance initiatives and corporate governance practices, including maintaining an effective system of internal controls over financial reporting.Q3, 2026

10x Genomics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:0A88 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TECHTECH74Outperform$11.41B66.088.22%0.55%0.94%122.38%
ADPTADPT64Neutral$4.61B-62.93-37.40%―17.91%16.01%
TWSTTWST52Neutral$7.64B-53.21-23.20%―22.00%-60.49%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
MRVIMRVI48Neutral$1.89B-16.31-31.86%―10.77%46.91%

* Healthcare Sector Average

Performance Comparison

0%200%400%600%GB:0A88TECHTWSTADPTMRVIALMRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:0A88 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:0A8810X Genomics55.0139.21248.21%
TECHBio-Techne72.6315.1326.32%
TWSTTwist Bioscience112.0086.55340.08%
ADPTAdaptive Biotechnologies28.4913.3488.05%
MRVIMaravai Lifesciences Holdings, Inc.7.283.78108.00%
ALMRAlamar Biosciences, Inc.30.648.6439.27%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.